Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: SRPT stock price vs SKX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SKX's multiple
Needs SKX P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · SKX FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
SKECHERS USA INC · implied price per share
Bear
$37.49
Base
$44.11
Bull
$50.72
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.02x
Net debt / EBITDA
Leverage against operating earnings
0.01x
-1.13x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$1.23B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
NIKE, Inc.
SRPT vs NKE
V F CORP
SRPT vs VFC
Crocs, Inc.
SRPT vs CROX
STEVEN MADDEN, LTD.
SRPT vs SHOO
CALERES INC
SRPT vs CAL
GENESCO INC
SRPT vs GCO
$934.46M
$84.60M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into positive margins and reverse its -61.6% ROIC, then the current 0.9x sales multiple could be attractive; otherwise, the weak quality scores and negative profitability argue for staying cautious relative to SKX.
SRPT is priced at 0.9x EV/Revenue and 0.9x P/S, which looks inexpensive on a revenue basis, but the market is clearly penalizing its losses and negative returns. SKX does not have comparable valuation multiples provided here, yet its profitability and balance sheet are far stronger, so the relative discount for SRPT appears driven by fundamentals rather than mispricing.
Supporting Metrics
